◎ Sugi Atlas

Atlas / Disease / Staphylococcus aureus infection

Staphylococcus aureus infection

disease
On this page

Summary

Staphylococcus aureus infection (MONDO:0005545) is a disease (an umbrella term covering 7 Mondo subtypes) with 7 cohort genes (7 GWAS associations across 3 studies) and 29 clinical trials. Top therapeutic interventions include clindamycin, penicillin g, and chlorhexidine gluconate.

At a glance

  • Umbrella term: 7 Mondo subtypes
  • Cohort genes: 7
  • GWAS associations: 7
  • Clinical trials: 29

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namestaphylococcus aureus infection
Mondo IDMONDO:0005545
EFOEFO:0005681
NCITC122576
SNOMED CT406602003
UMLSC1318973
MedGen232934
Is cancer (heuristic)no

Data availability: 7 GWAS associations (3 studies).

Disease family

An umbrella term covering 7 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › staphylococcal infection › staphylococcus aureus infection

Related subtypes (3): staphylococcal pneumonia, staphyloenterotoxemia, staphylococcal toxemia

Subtypes (7): impetigo, hordeolum, staphylococcal scalded skin syndrome, staphylococcus aureus pneumonia, methicillin-resistant staphylococcus aureus infectious disease, methicillin-susceptible staphylococcus aureus infectious disease, staphylococcus discitis

Genetics & variants

GWAS landscape

7 GWAS associations across 3 studies. Top hits map to 5 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs1152310741e-10HLA-DRB6 - HLA-DRB1T1.22
rs759182127e-09CTNNA2-AS1, CTNNA2?
rs43218649e-08TSBP1-AS1 - HLA-DRAA1.13
rs24550127e-07PDE4BT2.17
rs71525308e-07LINC02295 - RN7SL714PG1.61
rs38040473e-06TXNRD2C1.52
rs4700937e-06PNPLA5T1.63

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST003150DeLorenze GN20154,70145,344Polymorphisms in HLA Class II Genes Are Associated With Susceptibility to Staphylococcus aureus Infection in a White Population.
GCST002440Ye Z20143092,925Genome wide association study of SNP-, gene-, and pathway-based approaches to identify genes influencing susceptibility to Staphylococcus aureus infections.
GCST90651419Liu TY2025151213,110Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding0
Tier 2: splice/UTR1
Tier 3: regulatory0
Tier 4: intronic/intergenic6

MAF distribution

BucketVariants
common (>=0.05)5
low_freq (0.01-0.05)1
rare (<0.01)0
unknown1

Functional consequences

ConsequenceCount
intron_variant5
intergenic_variant1
3_prime_UTR_variant1

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs115231074632575268C>T0.05intergenic_variantHLA-DRB6 - HLA-DRB11e-10Tier 4: intronic/intergenic
rs75918212279510699A>Cintron_variantCTNNA2-AS1, CTNNA27e-09Tier 4: intronic/intergenic
rs4321864632431410C>A,T0.05intron_variantTSBP1-AS1 - HLA-DRA9e-08Tier 4: intronic/intergenic
rs2455012166055315A>C,G,T0.045intron_variantPDE4B7e-07Tier 4: intronic/intergenic
rs71525301498174878G>A0.367intron_variantLINC02295 - RN7SL714P8e-07Tier 4: intronic/intergenic
rs38040472219892114A>C,G,T0.281intron_variantTXNRD23e-06Tier 4: intronic/intergenic
rs4700932243880291T>A,C,G0.1473_prime_UTR_variantPNPLA57e-06Tier 2: splice/UTR

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 20 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
VRK1Orphanet:2254Pontocerebellar hypoplasia type 1
VRK1Orphanet:423894Microcephaly-complex motor and sensory axonal neuropathy syndrome
BCL11BOrphanet:662829Intellectual disability-speech delay-dysmorphic features-T cell abnormalities syndrome
TXNRD2Orphanet:154Familial isolated dilated cardiomyopathy
TXNRD2Orphanet:361Familial glucocorticoid deficiency
HLA-DRAOrphanet:505Graham Little-Piccardi-Lassueur syndrome
HLA-DRB1Orphanet:2073Narcolepsy type 1
HLA-DRB1Orphanet:220393Diffuse cutaneous systemic sclerosis
HLA-DRB1Orphanet:220402Limited cutaneous systemic sclerosis
HLA-DRB1Orphanet:220407Limited systemic sclerosis
HLA-DRB1Orphanet:3437Vogt-Koyanagi-Harada disease
HLA-DRB1Orphanet:397Giant cell arteritis
HLA-DRB1Orphanet:477738Pediatric multiple sclerosis
HLA-DRB1Orphanet:536Systemic lupus erythematosus
HLA-DRB1Orphanet:545Follicular lymphoma
HLA-DRB1Orphanet:703Bullous pemphigoid
HLA-DRB1Orphanet:747Autoimmune pulmonary alveolar proteinosis
HLA-DRB1Orphanet:797Sarcoidosis
HLA-DRB1Orphanet:83465Narcolepsy type 2
HLA-DRB1Orphanet:85414Systemic-onset juvenile idiopathic arthritis

Cohort genes → proteins

7 cohort genes, 7 distinct canonical proteins.

Evidence partition

SubsetGenes
gwas_only7

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
VRK1HGNC:12718ENSG00000100749Q99986Serine/threonine-protein kinase VRK1gwas
BCL11BHGNC:13222ENSG00000127152Q9C0K0B-cell lymphoma/leukemia 11Bgwas
TXNRD2HGNC:18155ENSG00000184470Q9NNW7Thioredoxin reductase 2, mitochondrialgwas
PNPLA5HGNC:24888ENSG00000100341Q7Z6Z6Patatin-like phospholipase domain-containing protein 5gwas
HLA-DRAHGNC:4947ENSG00000204287P01903HLA class II histocompatibility antigen, DR alpha chaingwas
HLA-DRB1HGNC:4948ENSG00000196126P01911HLA class II histocompatibility antigen, DRB1 beta chaingwas
PDE4BHGNC:8781ENSG00000184588Q073433’,5’-cyclic-AMP phosphodiesterase 4Bgwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
VRK1Serine/threonine-protein kinase VRK1Serine/threonine kinase involved in the regulation of key cellular processes including the cell cycle, nuclear condensation, transcription regulation, and DNA damage response.
BCL11BB-cell lymphoma/leukemia 11BKey regulator of both differentiation and survival of T-lymphocytes during thymocyte development in mammals.
TXNRD2Thioredoxin reductase 2, mitochondrialInvolved in the control of reactive oxygen species levels and the regulation of mitochondrial redox homeostasis.
PNPLA5Patatin-like phospholipase domain-containing protein 5Has abundant triacylglycerol lipase activity.
HLA-DRAHLA class II histocompatibility antigen, DR alpha chainAn alpha chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule.
HLA-DRB1HLA class II histocompatibility antigen, DRB1 beta chainA beta chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule.
PDE4B3’,5’-cyclic-AMP phosphodiesterase 4BHydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.

Protein-family classification

Druggable: 4 · Difficult: 2 · Unknown: 1 · Druggable fraction: 0.57

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Antibody/Immunoglobulin28.3×0.110
Kinase14.0×0.378
Transcription factor22.4×0.378
Enzyme (other)11.7×0.571
Other/Unknown10.3×0.997

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
VRK1KinaseyesProt_kinase_dom, Ser/Thr_kinase_AS, Kinase-like_dom_sf
BCL11BTranscription factornoZnf_C2H2_type, Znf_C2H2_sf, Dev/Hematopoietic_TF
TXNRD2Enzyme (other)yes1.8.1.9Pyr_nuc-diS_OxRdtase, Pyr_nucl-diS_OxRdtase_dimer, Thioredoxin/glutathione_Rdtase
PNPLA5Other/UnknownnoPNPLA_dom, Acyl_Trfase/lysoPLipase, PLPL
HLA-DRAAntibody/ImmunoglobulinyesMHC_II_a_N, Ig/MHC_CS, Ig_C1-set
HLA-DRB1Antibody/ImmunoglobulinyesMHC_II_b_N, Ig/MHC_CS, Ig_C1-set
PDE4BTranscription factorno3.1.4.53PDEase_catalytic_dom, HD/PDEase_dom, PDEase

Expression context

Cohort genes with no expression data: 0.

6 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)7
unknown0

Top tissues across cohort

TissueCohort genes
vermiform appendix2
bone marrow1
oocyte1
secondary oocyte1
cortical plate1
thymus1
upper leg skin1
apex of heart1
right adrenal gland cortex1
right lobe of liver1
epithelial cell of pancreas1
pancreatic ductal cell1
tibialis anterior1
leukocyte1
monocyte1
granulocyte1
right lung1
cartilage tissue1
corpus callosum1
subthalamic nucleus1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
VRK1286ubiquitousmarkeroocyte, bone marrow, secondary oocyte
BCL11B211broadmarkerthymus, upper leg skin, cortical plate
TXNRD2264ubiquitousmarkerright lobe of liver, right adrenal gland cortex, apex of heart
PNPLA553yestibialis anterior, pancreatic ductal cell, epithelial cell of pancreas
HLA-DRA132broadmarkermonocyte, leukocyte, vermiform appendix
HLA-DRB1131tissue_specificmarkervermiform appendix, granulocyte, right lung
PDE4B287ubiquitousmarkercorpus callosum, cartilage tissue, subthalamic nucleus

Protein interactions among cohort

Intra-cohort edges: 2.

Hub genes (top 10 by interactor count)

SymbolInteractor count
TXNRD23,712
HLA-DRB13,448
HLA-DRA3,244
VRK13,022
BCL11B2,523
PDE4B1,486
PNPLA5657

Intra-cohort edges

ABSources
HLA-DRAHLA-DRB1biogrid_interaction, intact, string_interaction
PNPLA5VRK1string_interaction

Structural data

PDB: 4 · AlphaFold-only: 3 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
HLA-DRAP01903140
HLA-DRB1P01911108
PDE4BQ0734343
VRK1Q9998626

AlphaFold-only cohort genes (top 30 by pLDDT)

SymbolUniProtpLDDT
PNPLA5Q7Z6Z681.06
BCL11BQ9C0K051.76
TXNRD2Q9NNW7

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 14. Enrichment computed across 7 evidence-associated genes (7 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 7 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Translocation of ZAP-70 to Immunological synapse2181.3×3e-04HLA-DRA, HLA-DRB1
Phosphorylation of CD3 and TCR zeta chains2155.4×3e-04HLA-DRA, HLA-DRB1
Co-inhibition by PD-12148.3×3e-04HLA-DRA, HLA-DRB1
Generation of second messenger molecules298.9×6e-04HLA-DRA, HLA-DRB1
Downstream TCR signaling236.7×0.003HLA-DRA, HLA-DRB1
Interferon gamma signaling235.9×0.003HLA-DRA, HLA-DRB1
MHC class II antigen presentation225.5×0.005HLA-DRA, HLA-DRB1
Initiation of Nuclear Envelope (NE) Reformation185.9×0.016VRK1
Formation of the embryonic stem cell BAF (esBAF) complex185.9×0.016BCL11B
Triglyceride catabolism168.0×0.016PNPLA5
DARPP-32 events168.0×0.016PDE4B
Nuclear Envelope Breakdown165.3×0.016VRK1
Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF)165.3×0.016BCL11B
Detoxification of Reactive Oxygen Species142.9×0.023TXNRD2

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 7 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
antigen processing and presentation of endogenous peptide antigen via MHC class II22407.4×1e-05HLA-DRA, HLA-DRB1
myeloid dendritic cell antigen processing and presentation21605.0×2e-05HLA-DRA, HLA-DRB1
regulation of T-helper cell differentiation21203.7×2e-05HLA-DRA, HLA-DRB1
positive regulation of CD4-positive, alpha-beta T cell activation21203.7×2e-05HLA-DRA, HLA-DRB1
positive regulation of CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation2963.0×3e-05HLA-DRA, HLA-DRB1
positive regulation of memory T cell differentiation2535.0×8e-05HLA-DRA, HLA-DRB1
peptide antigen assembly with MHC class II protein complex2300.9×2e-04HLA-DRA, HLA-DRB1
antigen processing and presentation of exogenous peptide antigen via MHC class II2155.3×7e-04HLA-DRA, HLA-DRB1
positive regulation of T cell mediated cytotoxicity2145.9×7e-04HLA-DRA, HLA-DRB1
positive regulation of immune response2137.6×7e-04HLA-DRA, HLA-DRB1
positive regulation of T cell activation2126.7×8e-04HLA-DRA, HLA-DRB1
response to oxygen radical12407.4×0.002TXNRD2
antigen processing and presentation of peptide or polysaccharide antigen via MHC class II12407.4×0.002HLA-DRA
regulation of interleukin-4 production12407.4×0.002HLA-DRB1
olfactory bulb axon guidance12407.4×0.002BCL11B
regulation of interleukin-10 production11203.7×0.004HLA-DRB1
positive T cell selection11203.7×0.004BCL11B
lymphoid lineage cell migration into thymus11203.7×0.004BCL11B
negative regulation of relaxation of cardiac muscle11203.7×0.004PDE4B
T cell receptor signaling pathway243.4×0.004HLA-DRB1, PDE4B
positive regulation of protein localization to chromatin1802.5×0.005VRK1
striatal medium spiny neuron differentiation1601.9×0.005BCL11B
Cajal body organization1601.9×0.005VRK1
post-embryonic camera-type eye development1601.9×0.005BCL11B
T cell receptor V(D)J recombination1601.9×0.005BCL11B
hematopoietic stem cell migration1601.9×0.005BCL11B
commitment of neuronal cell to specific neuron type in forebrain1401.2×0.008BCL11B
Golgi disassembly1401.2×0.008VRK1
positive regulation of T cell mediated immune response to tumor cell1343.9×0.008HLA-DRB1
negative regulation of adenylate cyclase-activating adrenergic receptor signaling pathway1343.9×0.008PDE4B

Therapeutics

Drugs indicated or in trials for this disease

No drug has an approved disease-direct ChEMBL indication for this disease.

20 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

DrugHighest phase
AurograbPhase 3
CefazolinPhase 3
ChlorhexidinePhase 3
ClindamycinPhase 3
CloxacillinPhase 3
DalbavancinPhase 3
DaptomycinPhase 3
FloxacillinPhase 3
FosfomycinPhase 3
LinezolidPhase 3
MupirocinPhase 3
SulfamethoxazolePhase 3
TigecyclinePhase 3
TrimethoprimPhase 3
VancomycinPhase 3
CholecalciferolPhase 2
Enoxaparin SodiumPhase 2
PetrolatumPhase 2
RetapamulinPhase 2
ThrombinPhase 2

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 2 · Phased (≥1): 2 · Undrugged: 5

Druggability breadth: 4 of 7 evidence-associated genes (57%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

SymbolExample approved molecule
PDE4BINAMRINONE

Top cohort targets by molecule count

SymbolMoleculesMax phase
PDE4B554
TXNRD233
VRK100
BCL11B00
PNPLA500
HLA-DRA00
HLA-DRB100

Drugs targeting cohort genes (top 30)

MoleculeMax phaseTargets in cohort
INAMRINONE4PDE4B
THEOPHYLLINE4PDE4B
VARDENAFIL4PDE4B
MILRINONE4PDE4B
LOSARTAN4PDE4B
SILDENAFIL4PDE4B
ROFLUMILAST4PDE4B
ENOXIMONE4PDE4B
ENSIFENTRINE4PDE4B
CRISABOROLE4PDE4B
APREMILAST4PDE4B
PENTOXIFYLLINE4PDE4B
TADALAFIL4PDE4B
DIPYRIDAMOLE4PDE4B
IBUDILAST4PDE4B
CURCUMIN3TXNRD2
TETOMILAST3PDE4B
MUFEMILAST3PDE4B
CILOMILAST3PDE4B
PAPAVERINE3PDE4B
ZATOLMILAST3PDE4B
ELLAGIC ACID2TXNRD2
STREPTONIGRIN2PDE4B
IMAZODAN2PDE4B
PELRINONE2PDE4B
PUMAFENTRINE2PDE4B
TOCLADESINE2PDE4B
AZD-64822PDE4B
DENBUFYLLINE2PDE4B
ENPROFYLLINE2PDE4B

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 2.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

SymbolAssaysType breakdown
PDE4B796Binding:755, Functional:29, ADMET:11, Toxicity:1
TXNRD291Binding:76, Functional:15
VRK174Binding:74
HLA-DRB117Binding:17

Cohort enzymes (BRENDA EC)

SymbolEC numbersNames
TXNRD21.8.1.9thioredoxin-disulfide reductase (NADPH)
PDE4B3.1.4.533’,5’-cyclic-AMP phosphodiesterase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

SymbolChEMBL assays
PDE4B796

Pharmacogenomics

Cohort genes with a PharmGKB record: 7; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

30 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

CompoundMax phaseCohort target (bioactivity)
INAMRINONE4PDE4B
THEOPHYLLINE4PDE4B
VARDENAFIL4PDE4B
MILRINONE4PDE4B
LOSARTAN4PDE4B
SILDENAFIL4PDE4B
ROFLUMILAST4PDE4B
ENOXIMONE4PDE4B
ENSIFENTRINE4PDE4B
CRISABOROLE4PDE4B
APREMILAST4PDE4B
PENTOXIFYLLINE4PDE4B
TADALAFIL4PDE4B
DIPYRIDAMOLE4PDE4B
IBUDILAST4PDE4B
CURCUMIN3TXNRD2
TETOMILAST3PDE4B
MUFEMILAST3PDE4B
CILOMILAST3PDE4B
PAPAVERINE3PDE4B
ZATOLMILAST3PDE4B
ELLAGIC ACID2TXNRD2
STREPTONIGRIN2PDE4B
IMAZODAN2PDE4B
PELRINONE2PDE4B
PUMAFENTRINE2PDE4B
TOCLADESINE2PDE4B
AZD-64822PDE4B
DENBUFYLLINE2PDE4B
ENPROFYLLINE2PDE4B

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)1PDE4B
BPhased (≥1) drug, not yet approved1TXNRD2
CDruggable family + PDB, no drug3VRK1, HLA-DRA, HLA-DRB1
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug2BCL11B, PNPLA5

Undrugged target profiles

5 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
VRK174—
BCL11B0—
PNPLA50—
HLA-DRA0—
HLA-DRB117—

Clinical trials & evidence

Clinical trials

Clinical trials: 29.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified10
PHASE17
PHASE44
PHASE1/PHASE24
PHASE32
PHASE21
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT04210505PHASE4ACTIVE_NOT_RECRUITINGNasal Decolonization of Dialysis Patients Noses
NCT05899140PHASE4RECRUITINGAdjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial
NCT06726395PHASE4RECRUITINGComparison of Cloxacillin and Benzylpenicillin in Penicillin Susceptible S. Aureus Bacteraemia
NCT06210594PHASE4COMPLETEDStaph Intervention for Effective Local Defense
NCT05117398PHASE3RECRUITINGDalbavancin Versus Standard Antibiotic Therapy for Catheter-related Bloodstream Infections Due to Staphylococcus Aureus
NCT01792804PHASE3COMPLETEDStaphylococcus Aureus Bacteremia Antibiotic Treatment Options
NCT06456424PHASE1/PHASE2ACTIVE_NOT_RECRUITINGBacteriophage Therapy for Methicillin-Sensitive Staphylococcus Aureus Prosthetic Joint Infection
NCT00572910PHASE2COMPLETEDA Study to Evaluate the Safety and Immunogenicity of V710 in Adults With Kidney Disease on Hemodialysis (V710-005)(COMPLETED)
NCT02282605PHASE1/PHASE2COMPLETEDStudy of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects
NCT04803708PHASE1/PHASE2COMPLETEDBacteriophage Therapy TP-102 in Diabetic Foot Ulcers
NCT06319235PHASE1/PHASE2UNKNOWNClinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®
NCT06368856PHASE1ACTIVE_NOT_RECRUITINGPharmacology of Mupirocin in Nasal Application in Healthy Volunteers: Monocentric Study
NCT07280598PHASE1NOT_YET_RECRUITINGSafety of Combined Intravenous Antibiotic and Bacteriophage Therapy in Adults With Cystic Fibrosis and Antibiotic-Resistant Lung Infections
NCT02804711PHASE1COMPLETEDA Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults
NCT03966040PHASE1COMPLETEDA Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults
NCT04784312PHASE1COMPLETEDA Clinical Study in Health Subjects to Evaluate 9MW1411 Injection
NCT06317688PHASE1UNKNOWNEffectiveness of Highly Purified Anhydrous (HPA) Lanolin Versus Extra-Virgin Coconut Oil in Preventing Subacute Lactation Mastitis
NCT06719219PHASE1COMPLETEDA First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus.
NCT02820883EARLY_PHASE1COMPLETEDA Study of a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults
NCT01879761Not specifiedACTIVE_NOT_RECRUITINGImmune Resolution After Staphylococcus Aureus Bacteremia
NCT04897971Not specifiedENROLLING_BY_INVITATIONSerum Based Diagnosis of and Monitoring of Infection Recovery in Orthopedic Spine Implant Infections
NCT05361135Not specifiedNOT_YET_RECRUITING18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
NCT01375621Not specifiedCOMPLETEDLivestock Contact and MRSA in Rural Areas
NCT02027389Not specifiedWITHDRAWNImpact of Rapid Detection of MRSA
NCT02741869Not specifiedWITHDRAWNPhotodisinfection for the Decolonization of Staphylococcus Aureus in Hemodialysis Patients
NCT04503252Not specifiedCOMPLETEDProbability of Target Attainment With Standard Intermittent Bolus Administration of Cefazolin in Patients With Complicated Infections Caused by Staphylococcus Aureus
NCT04712123Not specifiedUNKNOWNRecurrent S. Aureus Infections in Osteoarticular Infections
NCT04781569Not specifiedCOMPLETEDStaphylococcus Aureus Caught in Action at the Site of Infection
NCT06495697Not specifiedUNKNOWNPlasma Pharmacological Monitoring of M Penicillins in Methicillin-sensitive Staphylococcus Aureus Bacteremia

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
CLINDAMYCIN46
PENICILLIN G43
CHLORHEXIDINE GLUCONATE42
CLOXACILLIN42
MUPIROCIN42
CEFAZOLIN41
DALBAVANCIN41
DAPTOMYCIN41
LINEZOLID41
POVIDONE-IODINE41
FLOXACILLIN31
CHEMBL162802
CHEMBL479365802
CHEMBL164972201
CHEMBL428678401
CHEMBL474444401
CHEMBL477823901
CHEMBL478539201
CHEMBL617470501

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 70

This page pulls from 70 datasets indexed by BioBTree:

alphafoldantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsclinvarctd_gene_interactiondbsnpdepmapdiamond_similarityefoensemblentrezesm2_similarityfantom5_genefantom5_promotergenccgenerifgogtopdbgtopdb_interactiongwasgwas_studyhgncintactinterpromedgenmeshmimmondomondochildmondoparentncitorphanetpatentpatent_compoundpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assayreactomerefseqrhearnacentralsctidscxa_expressionscxa_gene_experimentsignorstring_interactiontranscriptufeatureumlsuniprot